Drug intelligence / Profile preview

ABS-501

Development stage: Preclinical
Lead developer: Absci
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ABS-501 is a novel, AI-designed anti-HER2 monoclonal antibody developed by Absci. It is engineered using zero-shot de novo AI technology to target HER2 with novel epitope interactions and demonstrates increased or equivalent affinity to trastuzumab in preclinical settings. The drug aims to be a best-in-class therapy for HER2-positive cancers, leveraging advanced design for improved efficacy and potentially differentiated clinical benefits compared to existing anti-HER2 therapies[1][3][4][8].

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on ABS-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABS-501.

Explore the full profile